<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00497601</url>
  </required_header>
  <id_info>
    <org_study_id>BSV-AMBE II-KA-706</org_study_id>
    <nct_id>NCT00497601</nct_id>
  </id_info>
  <brief_title>A Phase II Study To Assess Safety and Efficacy Of Short-Course Regimens Of Amphotericin B Emulsion In Kala-Azar</brief_title>
  <official_title>A Prospective, Single Center, Open-Label, Dose-Escalation Phase II Study To Assess Safety and Efficacy Of Short-Course Regimens Of Amphotericin B Emulsion In Treatment Na√Øve Or Resistant Cases Of Visceral Leishmaniasis (Kala-Azar).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Banaras Hindu University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Banaras Hindu University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is:&#xD;
&#xD;
        1. To evaluate the Safety and Efficacy of four different short-course regimens of&#xD;
           Amphotericin B emulsion in treatment of Kala-azar (visceral leishmaniasis) subjects who&#xD;
           are either treatment naive or treatment resistant to other antileishmanial drugs except&#xD;
           amphotericin B containing preparations.&#xD;
&#xD;
        2. To assess the safety and efficacy of single-bolus infusion of Amphotericin B emulsion in&#xD;
           treatment of Kala-azar.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. To evaluate the Safety and Efficacy of four different short-course regimens of&#xD;
           Amphotericin B emulsion in treatment of Kala-azar (visceral leishmaniasis) subjects who&#xD;
           are either treatment naive or treatment resistant to other antileishmanial drugs except&#xD;
           amphotericin B containing preparations.&#xD;
&#xD;
        2. To assess the safety and efficacy of single-bolus infusion of Amphotericin B emulsion in&#xD;
           treatment of Kala-azar.&#xD;
&#xD;
      Subjects will be administered the study drug in either of the following four dose levels in&#xD;
      an ascending manner, starting with the first dosage regimen:&#xD;
&#xD;
        -  7.5 mg/kg on day 1 and day3 (Regimen 1)&#xD;
&#xD;
        -  10 mg/kg on day 1, followed by 5 mg/kg on day 3 (Regimen 2)&#xD;
&#xD;
        -  12.5 mg/kg on day 1, followed by 2.5 mg/kg on day 3 (Regimen 3)&#xD;
&#xD;
        -  Single-bolus infusion of 15 mg/kg over 2-4 hours on day 1 (Regimen 4)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2007</start_date>
  <completion_date type="Actual">July 2008</completion_date>
  <primary_completion_date type="Actual">July 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical and parasitological cure at end of treatment and final cure (no relapse) at six months, no hematological, hepatic or renal toxicity</measure>
    <time_frame>one year</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Visceral Leishmaniasis</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Amphotericin B in fat emulsion (Amphomul) 7.5 mg/kg on day 1 and 3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Amphotericin B in fat emulsion (Amphomul) 10 mg/kg on day 1 and 5 mg/kg on day 3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Amphotericin B in fat emulsion (Amphomul) 12.5 mg/kg on day 1 and 2.5 mg/kg on day 3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Amphotericin B in fat emulsion (Amphomul) 15 mg/kg in a single dose administration on day 1</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amphotericin B fat emulsion in visceral leishmaniasis</intervention_name>
    <description>Amphotericin B in fat emulsion (Amphomul) 7.5 mg/kg on day 1 &amp; 3 in group A Amphotericin B in fat emulsion (Amphomul) 10 &amp; 5 mg/kg on day 1 &amp; 3 in group B Amphotericin B in fat emulsion (Amphomul) 12.5 &amp; 2.5 mg/kg on day 1 &amp; 3 in group C Amphotericin B in fat emulsion (Amphomul) 15 mg/kg on day 1 in group D</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
    <arm_group_label>C</arm_group_label>
    <arm_group_label>D</arm_group_label>
    <other_name>Amphomul</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amphotericin B fat emulsion</intervention_name>
    <description>Starting with 7.5 mg/kg on day 1 and 3, 10 and 5 mg/kg on day 1 and 3, 12.5 and 2.5 mg/kg on day 1 and 3 and finally 15 mg/kg on day 1</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
    <arm_group_label>C</arm_group_label>
    <arm_group_label>D</arm_group_label>
    <other_name>Amphomul</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amphotericin B in fat emulsion</intervention_name>
    <description>Starting with 7.5 mg/kg on day 1 and 3, 10 and 5 mg/kg on day 1 and 3, 12.5 and 2.5 mg/kg on day 1 and 3 and finally 15 mg/kg on day 1</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
    <arm_group_label>C</arm_group_label>
    <arm_group_label>D</arm_group_label>
    <other_name>Amphomul</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female subjects between 18 years and 65 years of age (both inclusive).&#xD;
&#xD;
          2. Subject/subject's legally acceptable representative is willing and able to give&#xD;
             written informed consent to participate in the study.&#xD;
&#xD;
          3. Treatment naive subjects having symptoms and/or signs of visceral leishmaniasis with&#xD;
             parasitological confirmation of Kala-azar (by splenic or bone marrow aspirate smear&#xD;
             examination).&#xD;
&#xD;
        If subjects are previously treated with other antileishmanial drugs except amphotericin B&#xD;
        containing preparations, they will be enrolled in the study only after clinical and&#xD;
        parasitological evidence that the disease is unresponsive to adequate treatment with other&#xD;
        drugs, and after an appropriate wash out period&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subjects with past history of treatment with Amphotericin B for Kala-azar.&#xD;
&#xD;
          2. Subjects positive for HIV infection.&#xD;
&#xD;
          3. Concomitant life threatening or serious disease.&#xD;
&#xD;
          4. Concurrent malaria (malarial parasite test to be negative prior to study treatment&#xD;
             administration), tuberculosis or bacterial pneumonia.&#xD;
&#xD;
          5. Haemoglobin &lt; 6 gm/dl, total leukocyte count &lt; 1,500/cmm, platelet count &lt; 50,000/cmm&#xD;
&#xD;
          6. Abnormal liver and renal functions (BUN and serum creatinine &gt; 1.5 times upper limit&#xD;
             of normal (ULN), AST/ALT &gt; 2.5 times ULN, and bilirubin &gt; 1.5 times ULN).&#xD;
&#xD;
          7. Pregnant or nursing women.&#xD;
&#xD;
          8. Known hypersensitivity to Amphotericin B or inactive ingredients of study drug&#xD;
             formulation.&#xD;
&#xD;
          9. Subjects receiving any of the medications prohibited by the study protocol.&#xD;
&#xD;
         10. Evidence of significant haematological, cardiac, hepatic, renal, respiratory,&#xD;
             neurological or metabolic disease or any condition which, in the opinion of the&#xD;
             investigator, might interfere with the evaluation of the study objectives.&#xD;
&#xD;
         11. Simultaneous participation in another trial or received any investigational product &lt;&#xD;
             30 days prior to enrolment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shyam Sundar</last_name>
    <role>Principal Investigator</role>
    <affiliation>Banaras Hindu University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kala-azar Medical Research Center</name>
      <address>
        <city>Muzaffarpur</city>
        <state>Bihar</state>
        <zip>842001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>September 2008</verification_date>
  <study_first_submitted>July 5, 2007</study_first_submitted>
  <study_first_submitted_qc>July 5, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 6, 2007</study_first_posted>
  <last_update_submitted>September 11, 2008</last_update_submitted>
  <last_update_submitted_qc>September 11, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 12, 2008</last_update_posted>
  <keyword>Visceral Leishmaniasis</keyword>
  <keyword>Amphotericin B</keyword>
  <keyword>Fat emulsion</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leishmaniasis</mesh_term>
    <mesh_term>Leishmaniasis, Visceral</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amphotericin B</mesh_term>
    <mesh_term>Liposomal amphotericin B</mesh_term>
    <mesh_term>Soybean oil, phospholipid emulsion</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

